Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,General Neuroscience
Link
http://link.springer.com/content/pdf/10.1186/1471-2202-13-33.pdf
Reference23 articles.
1. Baggio LL, Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007, 132 (6): 2131-2157. 10.1053/j.gastro.2007.03.054.
2. Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006, 368 (9548): 1696-1705. 10.1016/S0140-6736(06)69705-5.
3. Faludi P, Brodows R, Burger J, Ivanyi T, Braun DK: The effect of exenatide re-exposure on safety and efficacy. Peptides. 2009, 30 (9): 1771-1774. 10.1016/j.peptides.2009.06.026.
4. Vilsboll T: Liraglutide: a new treatment for type 2 diabetes. Drugs Today (Barc). 2009, 45 (2): 101-113.
5. Christensen M, Knop FK, Vilsboll T, Holst JJ: Lixisenatide for type 2 diabetis mellitus. Expert Opin Investig Drugs. 2011, 20 (4): 549-557.
Cited by 394 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges;Life Sciences;2024-10
2. IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target;Pharmacological Research;2024-09
3. Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population‐Based Cohort Study;Movement Disorders;2024-08-27
4. The Efficacy of GLP-1 Agonists in Treating Substance Use Disorder in Patients;Journal of Addiction Medicine;2024-08-02
5. Current Therapeutic Options and Repurposed Drugs for Neurodegeneration;Advances in Diagnostics and Immunotherapeutics for Neurodegenerative Diseases;2024-07-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3